tat Gene Products, Human Immunodeficiency Virus

"tat Gene Products, Human Immunodeficiency Virus" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Proteins encoded by the TAT GENES of the HUMAN IMMUNODEFICIENCY VIRUS.

Descriptor ID	D054322
MeSH Number(s)	D12.776.260.755.199.500 D12.776.930.900.199.500 D12.776.964.775.562.773 D12.776.964.925.984.400.500
Concept/Terms	tat Gene Products, Human Immunodeficiency Virus tat Gene Products, Human Immunodeficiency Virus Trans-Acting Transcription Factor, HIV Trans Acting Transcription Factor, HIV HIV tat Protein tat Protein, HIV HIV Transacting Transcription Protein

Below are MeSH descriptors whose meaning is more general than "tat Gene Products, Human Immunodeficiency Virus".

Chemicals and Drugs [D]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
DNA-Binding Proteins [D12.776.260]
Trans-Activators [D12.776.260.755]
Gene Products, tat [D12.776.260.755.199]
tat Gene Products, Human Immunodeficiency Virus [D12.776.260.755.199.500]
Transcription Factors [D12.776.930]
Trans-Activators [D12.776.930.900]
Gene Products, tat [D12.776.930.900.199]
tat Gene Products, Human Immunodeficiency Virus [D12.776.930.900.199.500]
Viral Proteins [D12.776.964]
Retroviridae Proteins [D12.776.964.775]
Human Immunodeficiency Virus Proteins [D12.776.964.775.562]
tat Gene Products, Human Immunodeficiency Virus [D12.776.964.775.562.773]
Viral Regulatory and Accessory Proteins [D12.776.964.925]
Trans-Activators [D12.776.964.925.984]
Gene Products, tat [D12.776.964.925.984.400]
tat Gene Products, Human Immunodeficiency Virus [D12.776.964.925.984.400.500]

Below are MeSH descriptors whose meaning is related to "tat Gene Products, Human Immunodeficiency Virus".

Below are MeSH descriptors whose meaning is more specific than "tat Gene Products, Human Immunodeficiency Virus".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "tat Gene Products, Human Immunodeficiency Virus" by people in this website by year, and whether "tat Gene Products, Human Immunodeficiency Virus" was a major or minor topic of these publications.

Bar chart showing 35 publications over 19 distinct years, with a maximum of 6 publications in 2005

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1994	0	3	3
1995	0	1	1
2002	0	5	5
2004	0	2	2
2005	0	6	6
2006	0	2	2
2007	0	1	1
2008	1	0	1
2009	0	1	1
2011	0	1	1
2012	1	2	3
2013	1	0	1
2014	1	0	1
2015	0	1	1
2017	0	2	2
2018	1	0	1
2019	1	0	1
2021	1	0	1
2022	0	1	1

Below are the most recent publications written about "tat Gene Products, Human Immunodeficiency Virus" by people in Profiles.

Xu C, Yadav-Samudrala BJ, Xu C, Nath B, Mistry T, Jiang W, Niphakis MJ, Cravatt BF, Mukhopadhyay S, Lichtman AH, Ignatowska-Jankowska BM, Fitting S. Inhibitory Neurotransmission Is Sex-Dependently Affected by Tat Expression in Transgenic Mice and Suppressed by the Fatty Acid Amide Hydrolase Enzyme Inhibitor PF3845 via Cannabinoid Type-1 Receptor Mechanisms. Cells. 2022 03 02; 11(5).

View in: PubMed
Alanazi A, Ivanov A, Kumari N, Lin X, Wang S, Kovalskyy D, Nekhai S. Targeting Tat-TAR RNA Interaction for HIV-1 Inhibition. Viruses. 2021 10 06; 13(10).

View in: PubMed
Jacobs IR, Xu C, Hermes DJ, League AF, Xu C, Nath B, Jiang W, Niphakis MJ, Cravatt BF, Mackie K, Mukhopadhyay S, Lichtman AH, Ignatowska-Jankowska BM, Fitting S. Inhibitory Control Deficits Associated with Upregulation of CB1R in the HIV-1 Tat Transgenic Mouse Model of Hand. J Neuroimmune Pharmacol. 2019 12; 14(4):661-678.

View in: PubMed
Ivanov A, Lin X, Ammosova T, Ilatovskiy AV, Kumari N, Lassiter H, Afangbedji N, Niu X, Petukhov MG, Nekhai S. HIV-1 Tat phosphorylation on Ser-16 residue modulates HIV-1 transcription. Retrovirology. 2018 05 23; 15(1):39.

View in: PubMed
Hu G, Yelamanchili S, Kashanchi F, Haughey N, Bond VC, Witwer KW, Pulliam L, Buch S. Proceedings of the 2017 ISEV symposium on "HIV, NeuroHIV, drug abuse, & EVs". J Neurovirol. 2017 Dec; 23(6):935-940.

View in: PubMed
Xu C, Hermes DJ, Nwanguma B, Jacobs IR, Mackie K, Mukhopadhyay S, Lichtman AH, Ignatowska-Jankowska B, Fitting S. Endocannabinoids exert CB1 receptor-mediated neuroprotective effects in models of neuronal damage induced by HIV-1 Tat protein. Mol Cell Neurosci. 2017 09; 83:92-102.

View in: PubMed
Anand P, O'Neil A, Lin E, Douglas T, Holford M. Tailored delivery of analgesic ziconotide across a blood brain barrier model using viral nanocontainers. Sci Rep. 2015 Aug 03; 5:12497.

View in: PubMed
Ammosova T, Platonov M, Ivanov A, Kont YS, Kumari N, Kehn-Hall K, Jerebtsova M, Kulkarni AA, Uren A, Kovalskyy D, Nekhai S. 1E7-03, a low MW compound targeting host protein phosphatase-1, inhibits HIV-1 transcription. Br J Pharmacol. 2014 Nov; 171(22):5059-75.

View in: PubMed
Nookala AR, Shah A, Noel RJ, Kumar A. HIV-1 Tat-mediated induction of CCL5 in astrocytes involves NF-?B, AP-1, C/EBPa and C/EBP? transcription factors and JAK, PI3K/Akt and p38 MAPK signaling pathways. PLoS One. 2013; 8(11):e78855.

View in: PubMed
Van Duyne R, Guendel I, Jaworski E, Sampey G, Klase Z, Chen H, Zeng C, Kovalskyy D, El Kouni MH, Lepene B, Patanarut A, Nekhai S, Price DH, Kashanchi F. Effect of mimetic CDK9 inhibitors on HIV-1-activated transcription. J Mol Biol. 2013 Feb 22; 425(4):812-29.

View in: PubMed

People

Explore

Similar Concepts

Top Journals